SVRA
Savara Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
Market Cap: 734 Million
Primary Exchange: NASDAQ
Website: http://savarapharma.com/
Shares Outstanding: 135 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.5721579019776357
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1999 trading days
From: 2014-01-22 To: 2024-03-07
Lowest Point:
Savara to Present at the JMP Securities Life Sciences Conference
via: Business Wire at 2019-06-13 12:02:00:000
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, and Chief Operating Officer, Taneli Jouhikainen, will present at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 11:30 a.m. East… read more...
Microcaps mostly among midday movers
via: SeekingAlpha at 2019-06-13 08:41:38:000
Gainers: Coda Octopus Group (NASDAQ: CODA ) +40% . Mmtec (NASDAQ: MTC ) +30% . Red Robin Gourmet Burgers (NASDAQ: RRGB ) +29% . DryShips (NASDAQ: DRYS ) +24% . Cemtrex (NASDAQ: CETX ) +21% . Ruhnn Holding Limited (NASDAQ: RUHN ) +21% . RH (NYSE: RH ) +20% . Aeterna Zentaris (N… read more...
Sell-siders downgrade Savara after Molgradex flop
via: SeekingAlpha at 2019-06-13 08:03:39:000
In classic after-the-fact fashion, sell-side analysts cut their ratings on Savara ( SVRA -75.1% ) after its failed late-stage study of Molgradex in a rare autoimmune disorder called alveolar pulmonary proteinosis (aPAP). More news on: Savara Inc., Healthcare stocks news, Stocks on the … read more...
SVRA and HEB among premarket losers
via: SeekingAlpha at 2019-06-13 05:09:48:000
Savara (NASDAQ: SVRA ) -76% as Molgradex flunks late-stage aPAP study. More news on: Savara Inc., Hemispherx Biopharma, Inc., NovaBay Pharmaceuticals, Inc., Stocks on the move, Read more … read more...
Roth likes Village Farms in premarket analyst action
via: SeekingAlpha at 2019-06-13 03:36:02:000
Argenx (NASDAQ: AGRX ) initiated with Buy rating and 140 (28% upside) price target at Kepler Cheuvreux. More news on: Agile Therapeutics, Inc., Village Farms International, Inc., Savara Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
LULU, RH and TLRD among after hour movers
via: SeekingAlpha at 2019-06-12 13:33:29:000
Gainers: RH +22.4% . FRME +8.1% . OXM +3.9% . LULU +3.6% . CIH +3.1% . More news on: RH, First Merchants Corporation, Oxford Industries, Inc., Stocks on the move, , News on ETFs Read more … read more...
Savara's Molgradex flunks late-stage aPAP study
via: SeekingAlpha at 2019-06-12 12:26:28:000
Thinly traded micro cap Savara (NASDAQ: SVRA ) is poised for a significant down move after announcing that its Phase 3 clinical trial, IMPALA , evaluating lead drug Molgradex in patients with autoimmune alveolar pulmonary proteinosis (aPAP) failed to sufficiently separate from placeb… read more...
Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)
via: Business Wire at 2019-06-12 12:02:00:000
The study did not meet its primary endpoint of alveolar-arterial oxygen gradient ( A-aDO 2 ) The study showed statistically significant improvement in the St. Georges Respiratory Questionnaire (SGRQ), a key secondary endpoint Adverse event frequencies were similar bet… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|---|---|---|---|---|---|
| 2017-04-28 | 70.0 | 1.0 | 70.0 |